ScienceDaily (Dec. 2, 2009) — Using routine computed tomography (CT) imaging to analyze form and structural changes to colorectal liver metastasis after bevacizumab and chemotherapy may predict overall survival, according to research from The University of Texas M. D. Anderson Cancer Center.
The findings are published in the Dec. 2 issue of JAMA.
When combined with chemotherapy, the angiogenesis inhibitor bevacizumab, also known as Avastin, is associated with both improved survival in those with metastatic colorectal cancer and higher rates of pathologic response in patients undergoing surgical resection of colorectal liver metastases. The monoclonal antibody was approved for use in the front line setting of metastatic colorectal cancer in 2004.
However, the therapy presents a unique set of challenges, explains Jean-Nicolas Vauthey, M.D., professor in M. D. Anderson's Department of Surgical Oncology.
source: Science Daily Release
Subscribe to:
Post Comments (Atom)
2 comments:
That a very informative blog i come across imaging news ct thats good
thanks for the post
have a good Health
This is good post regarding CT Imaging taken post that may predict Survival in patients with Metastatic Colorectal Cancer, this was infomative blog post,
thanks for post.
New York Life Settlement
Post a Comment